Doximity operates the definitive digital platform for U.S. medical professionals, with over 3 million registered members representing more than 85 percent of U.S. physicians across every specialty and geography. The quarter marked a decisive inflection in the company's AI strategy as the Clinical AI Suite, comprising Ask, Scribe, and Dialer, moved from feature extension to core engagement driver, with quarterly unique active providers using workflow tools climbing 31 percent year-over-year to 0.81 million. Revenue growth has moderated to 13 percent in fiscal 2026 from 20 percent in the prior year, reflecting both the law of large numbers at a $645 million run rate and a deliberate shift toward higher-quality subscription expansion within existing pharma relationships rather than new logo acquisition.
The investment thesis rests on three variables. Net revenue retention at 109 percent signals that the existing customer base continues to expand spending, though the deceleration from 119 percent warrants monitoring as a leading indicator of pharma marketing budget cycles. Operating leverage remains intact despite elevated AI investment: gross margin held at 89 percent while R&D grew 40 percent year-over-year to $131 million, reflecting the capital intensity of building proprietary clinical AI rather than margin pressure. The balance sheet fortress of $688 million in cash and marketable securities against zero debt provides optionality for continued share repurchase, with $401 million remaining authorized, and potential tuck-in acquisitions to deepen the workflow moat.
Binary market implications center on whether the Clinical AI Suite can sustain workflow engagement growth that ultimately pulls through to higher Marketing Solutions pricing power. Confirmation arrives if quarterly active providers on workflow tools sustain above 30 percent year-over-year growth and net revenue retention stabilizes above 105 percent, supporting a re-rating toward the 25 times forward revenue multiple commanded by SaaS platforms with comparable retention and margin profiles. The thesis breaks if net revenue retention falls below 100 percent for two consecutive quarters, signaling structural pharma budget contraction, or if operating margins compress below 30 percent as AI inference costs scale faster than subscription revenue.